

Table S1. Results of one-way ANOVA or Kruskal-Wallis test investigating the effects of MS and early-life SAL/VEH treatment on mRNA and protein expression of ER stress, UPR and apoptosis markers in the mPFC of juvenile and preadolescent rats

Parameter	PND 15	PND 26
	Statistic	Statistic
Hspa5 mRNA HSPA5 protein	$H_3 = 17.02, p = 0.0007$ $F_{3,20} = 3.35, p = 0.039$	$F_{3,20} = 11.23, p < 0.0001$ $H_3 = 0.99, p = 0.803$
Eif2ak3 mRNA PERK protein p-PERK (Thr980) protein	$F_{3,20} = 1.78, p = 0.183$ $F_{3,20} = 1.47, p = 0.253$ $F_{3,20} = 5.93, p = 0.005$	$F_{3,20} = 1.51, p = 0.242$ $F_{3,20} = 0.26, p = 0.850$ $H_3 = 0.67, p = 0.879$
Ern1 mRNA IRE1 α protein p-IRE1 α (S724) protein	$F_{3,20} = 1.70, p = 0.200$ $F_{3,20} = 0.52, p = 0.672$ $F_{3,20} = 3.88, p = 0.024$	$F_{3,20} = 11.15, p = 0.0002$ $H_3 = 3.18, p = 0.365$ $F_{3,20} = 2.88, p = 0.061$
Atf6 mRNA ATF protein	$F_{3,20} = 1.49, p = 0.248$ $F_{3,20} = 1.57, p = 0.229$	$F_{3,20} = 4.42, p = 0.015$ $F_{3,20} = 0.90, p = 0.459$
Eif2a mRNA eIF2 α protein p-eIF2 α (S51) protein	$H_3 = 18.83, p = 0.003$ $F_{3,20} = 6.10, p = 0.004$ $F_{3,20} = 4.97, p = 0.050$	$H_3 = 1.67, p = 0.643$ $F_{3,20} = 1.10, p = 0.373$ $H_3 = 1.63, p = 0.652$
Casp9 mRNA Caspase-9 protein Cleaved caspase-9 protein	$F_{3,20} = 5.11, p = 0.009$ $F_{3,20} = 1.59, p = 0.222$ $F_{3,20} = 2.09, p = 0.135$	$H_3 = 6.76, p = 0.080$ $F_{3,20} = 0.56, p = 0.647$ $F_{3,20} = 0.49, p = 0.693$
Casp3 mRNA Cleaved caspase-3 protein	$H_3 = 7.13, p = 0.068$ $F_{3,20} = 1.06, p = 0.389$	$H_3 = 10.82, p = 0.013$ $H_3 = 9.53, p = 0.0500$
Casp12 mRNA Caspase-12 protein Cleaved caspase-12 protein	$F_{3,20} = 5.36, p = 0.007$ $F_{3,20} = 0.62, p = 0.061$ $F_{3,20} = 0.52, p = 0.670$	$F_{3,20} = 5.26, p = 0.008$ $F_{3,20} = 0.47, p = 0.708$ $F_{3,20} = 0.36, p = 0.785$
Bax mRNA Bax protein	$F_{3,20} = 15.34, p < 0.0001$ $F_{3,20} = 2.72, p = 0.072$	$H_3 = 1.32, p = 0.724$ $F_{3,20} = 1.79, p = 0.189$
Bcl2 mRNA Bcl2 protein	$F_{3,20} = 2.67, p = 0.075$ $F_{3,20} = 1.60, p = 0.221$	$F_{3,20} = 12.02, p = 0.0001$ $F_{3,20} = 1.91, p = 0.160$
Bax/Bcl2 mRNA Bax/Bcl2 protein	$F_{3,20} = 11.29, p < 0.0001$ $F_{3,20} = 0.51, p = 0.679$	$H_3 = 16.61, p = 0.0009$ $H_3 = 11.29, p = 0.010$

Statistically significant differences are given in bold. *Abbreviations:* mPFC, medial prefrontal cortex; MS, maternal separation; PND, postnatal day; SAL, salubrinal; VEH, vehicle.

Table S2. Results of ANOVA or Kruskal-Wallis test investigating the effects of MS and early-life SAL/VEH treatment on behavioral phenotype of preadolescent and adult rats

Parameter	PND 26 Statistic	PND 70 Statistic
Light/dark box:		
% Time in light	$H_3 = 11.97, p = 0.007$	$F_{3,45} = 4.51, p = 0.007$
% Distance traveled in light	$H_3 = 12.87, p = 0.005$	$H_3 = 12.83, p = 0.005$
Transitions (N)	$H_3 = 8.58, p = 0.035$	$H_3 = 6.0, p = 0.112$
Fear memory:		
FC acquisition	$F_{3,40} = 1.82, p = 0.160$	$F_{3,40} = 0.99, p = 0.406$
CFC expression	$F_{3,40} = 4.20, p = 0.011$	$F_{3,40} = 3.28, p = 0.031$
AFC expression	$H_3 = 2.91, p = 0.405$	$F_{3,40} = 1.92, p = 0.141$
CFC recall	N.A.	$H_3 = 4.14, p = 0.246$
AFC recall	N.A.	$H_3 = 1.63, p = 0.653$
Sucrose preference	$F_{3,36} = 3.82, p = 0.018$	$H_3 = 0.21, p = 0.996$
Novelty-induced locomotion	$F_{3,36} = 2.91, p = 0.047$	N/A
Amphetamine-induced locomotion:		
Effect of early-life treatment	$F_{3,36} = 3.53, p = 0.024$	$F_{3,36} = 7.17, p = 0.0007$
Effect of amphetamine	$F_{1,36} = 338.20, p < 0.0001$	$F_{1,36} = 203.27, p < 0.0001$
Effect of early-life x amphetamine	$F_{3,36} = 3.68, p = 0.021$	$F_{3,36} = 7.96, p = 0.0003$

Statistically significant differences are given in bold. *Abbreviations:* AFC, auditory fear conditioning; CFC, contextual fear conditioning; FC, fear conditioning; MS, maternal separation; N/A; not assessed; PND, postnatal day; SAL, salubrinal; VEH, vehicle.